NCT03102320: Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

NCT03102320
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: Mesothelin+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Tumor(s) must express mesothelin
Exclusions: Symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis
https://ClinicalTrials.gov/show/NCT03102320

Comments are closed.

Up ↑